Mary Falcone1, Wen Cao1, Leah Bernardo1, Rachel F Tyndale2, James Loughead1, Caryn Lerman3. 1. Center for Interdisciplinary Research on Nicotine Addiction, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania. 2. Campbell Family Mental Health Research Institute, University of Toronto, Toronto, Ontario, Canada; Centre for Addiction and Mental Health, and Departments of Psychiatry and Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada. 3. Center for Interdisciplinary Research on Nicotine Addiction, Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: clerman@upenn.edu.
Abstract
BACKGROUND: Inherited differences in the rate of metabolism of nicotine, the addictive chemical in tobacco, affect smoking behavior and quitting success. The nicotine metabolite ratio (3'-hydroxycotinine/cotinine) is a reliable measure of nicotine clearance and a well-validated predictive biomarker of response to pharmacotherapy. To clarify the mechanisms underlying these associations, we investigated the neural responses to smoking cues in normal and slow nicotine metabolizers. METHODS: Treatment-seeking smokers (N = 69; 30 slow metabolizers and 39 normal metabolizers) completed a visual cue reactivity task during functional magnetic resonance imaging on two separate occasions: once during smoking satiety and once after 24 hours of smoking abstinence. RESULTS: In whole-brain analysis, normal (compared with slow) metabolizers exhibited heightened abstinence-induced neural responses to smoking cues in the left caudate, left inferior frontal gyrus, and left frontal pole. These effects were more pronounced when extreme groups of slow and normal metabolizers were examined. Greater activation in the left caudate and left frontal pole was associated with abstinence-induced subjective cravings to smoke. CONCLUSIONS: Inherited differences in rate of nicotine elimination may drive neural responses to smoking cues during early abstinence, providing a plausible mechanism to explain differences in smoking behaviors and response to cessation treatment. Normal metabolizers may benefit from adjunctive behavioral smoking cessation treatments, such as cue exposure therapy.
BACKGROUND: Inherited differences in the rate of metabolism of nicotine, the addictive chemical in tobacco, affect smoking behavior and quitting success. The nicotine metabolite ratio (3'-hydroxycotinine/cotinine) is a reliable measure of nicotine clearance and a well-validated predictive biomarker of response to pharmacotherapy. To clarify the mechanisms underlying these associations, we investigated the neural responses to smoking cues in normal and slow nicotine metabolizers. METHODS: Treatment-seeking smokers (N = 69; 30 slow metabolizers and 39 normal metabolizers) completed a visual cue reactivity task during functional magnetic resonance imaging on two separate occasions: once during smoking satiety and once after 24 hours of smoking abstinence. RESULTS: In whole-brain analysis, normal (compared with slow) metabolizers exhibited heightened abstinence-induced neural responses to smoking cues in the left caudate, left inferior frontal gyrus, and left frontal pole. These effects were more pronounced when extreme groups of slow and normal metabolizers were examined. Greater activation in the left caudate and left frontal pole was associated with abstinence-induced subjective cravings to smoke. CONCLUSIONS: Inherited differences in rate of nicotine elimination may drive neural responses to smoking cues during early abstinence, providing a plausible mechanism to explain differences in smoking behaviors and response to cessation treatment. Normal metabolizers may benefit from adjunctive behavioral smoking cessation treatments, such as cue exposure therapy.
Authors: Hans Rollema; Mihály Hajós; Patricia A Seymour; Rouba Kozak; Mark J Majchrzak; Victor Guanowsky; Weldon E Horner; Doug S Chapin; William E Hoffmann; David E Johnson; Stafford McLean; Jody Freeman; Kathryn E Williams Journal: Biochem Pharmacol Date: 2009-06-06 Impact factor: 5.858
Authors: F Patterson; R A Schnoll; E P Wileyto; A Pinto; L H Epstein; P G Shields; L W Hawk; R F Tyndale; N Benowitz; C Lerman Journal: Clin Pharmacol Ther Date: 2008-04-02 Impact factor: 6.875
Authors: James Loughead; E Paul Wileyto; Kosha Ruparel; Mary Falcone; Ryan Hopson; Ruben Gur; Caryn Lerman Journal: Neuropsychopharmacology Date: 2014-12-03 Impact factor: 7.853
Authors: Robert A Schnoll; Morgan Thompson; Katrina Serrano; Frank Leone; David Metzger; Ian Frank; Robert Gross; Karam Mounzer; Rachel F Tyndale; Jessica Weisbrot; Miles Meline; Ronald G Collman; Rebecca L Ashare Journal: J Acquir Immune Defic Syndr Date: 2019-02-01 Impact factor: 3.731
Authors: Cheyenne Allenby; Mary Falcone; Rebecca L Ashare; Wen Cao; Leah Bernardo; E Paul Wileyto; Jens Pruessner; James Loughead; Caryn Lerman Journal: Nicotine Tob Res Date: 2020-05-26 Impact factor: 4.244
Authors: Rebecca L Ashare; Morgan Thompson; Frank Leone; David Metzger; Robert Gross; Karam Mounzer; Rachel F Tyndale; Caryn Lerman; Martin C Mahoney; Paul Cinciripini; Tony P George; Ronald G Collman; Robert Schnoll Journal: AIDS Date: 2019-05-01 Impact factor: 4.177
Authors: Gerald W Valentine; Elise E DeVito; Peter I Jatlow; Ralitza Gueorguieva; Mehmet Sofuoglu Journal: J Psychopharmacol Date: 2018-05-23 Impact factor: 4.153
Authors: Paul Faulkner; Dara G Ghahremani; Rachel F Tyndale; Chelsea M Cox; Ari S Kazanjian; Neil Paterson; Shahrdad Lotfipour; Gerhard S Hellemann; Nicole Petersen; Celia Vigil; Edythe D London Journal: Neuropsychopharmacology Date: 2017-01-24 Impact factor: 7.853
Authors: Sarah W Yip; Iris M Balodis; Kathleen M Carroll; Suchitra Krishnan-Sarin; Marc N Potenza Journal: Drug Alcohol Depend Date: 2016-08-21 Impact factor: 4.492